This page is the continuation of references in support of Section 8b Breast Cancer Treatment.

REFERENCES

EBCTCG (Early Breast Cancer Trialists’ Collaborative Group), McGale, P., Taylor, C., Correa, C., et al. (2014). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383(9935), 2127-35. (Retrieved November 26^th 2014): https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60488-8/fulltext

Farmer, H., McCabe, N., Lord, C.J. et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-21. (Retrieved November 26^th 2014):  https://www.nature.com/articles/nature03445

Hughes, L.L., Wang, M., Page, D.L., Gray, R., Solin, L.J., Davidson, N.E., Lowen, M.A., Ingle, J.N., Recht, A., Wood, W.C. (2009). Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27(32), 5319. (Retrieved November 6^th 2014): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2773217/

Miller K,, Wang, M., Gralow, J. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666–2676. (Retrieved November 27^th 2014): https://www.nejm.org/doi/full/10.1056/NEJMoa072113

National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. Retrieved November 6^th 2014): http://www.nccn.org/professionals/physician_gls/f_guidelines.asp

Oppong, B.A., King, T.A. (2011). Recommendations for women with lobular carcinoma in situ (LCIS). Oncology 25(11), 1051-6. (Retrieved November 26^th 2014): https://www.ncbi.nlm.nih.gov/pubmed/22106556

Staley, H., McCallum, I., Bruce, J. (2012). Postoperative tamoxifen for ductal carcinoma in situ. Cochrane Database Syst Rev 10, CD007847. (Retrieved November 6^th 2014): https://www.ncbi.nlm.nih.gov/pubmed/23076938